Drug-induced bile duct injury: New agents, new mechanisms

Jean Yves Scoazec

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    5 Citations (Scopus)

    Résumé

    Purpose of reviewDrug-induced bile duct injury can be caused by a long list of agents. In most cases, damage is because of T-cell-mediated idiosyncratic reactions. Recently, a number of new agents, including not only drugs but also herbal supplements, have been incriminated and new mechanisms of bile duct injury have emerged. This review will focus on these new data.Recent findingsNew members of drug families already known to be responsible for bile duct injury have been incriminated. New players have been identified, such as herbal supplements, like kratom, and recreational drugs, such as ketamine used outside the medical setting. Anticytokine monoclonal antibodies are rarely involved. In contrast, antineoplastic treatments are of growing concern, especially immune checkpoint inhibitors, which induce immune-related adverse effects because of the excessive stimulation of the immune system and its lack of regulation.SummaryTwo patterns of bile duct injury are recognized. Drug-induced small-duct cholangiopathies target the smaller bile ducts; acute injuries eventually progress to chronic disease in the form of the vanishing bile duct syndrome. Drug-induced sclerosing cholangitis target large bile ducts, with a protracted chronic course; the onset of symptoms may be delayed after drug discontinuation; potentially severe, life-threatening complications can occur.

    langue originaleAnglais
    Pages (de - à)83-88
    Nombre de pages6
    journalCurrent Opinion in Gastroenterology
    Volume38
    Numéro de publication2
    Les DOIs
    étatPublié - 1 mars 2022

    Contient cette citation